Duchenne muscular dystrophy (DMD) is caused by a mutation in the DMD gene that prevents dystrophin production, leading to progressive muscle weakness and early mobility challenges. The 2018 DMD ...
New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular dystrophy (DMD). In preclinical DMD mouse models, investigators demonstrated ...
Hosted on MSN
Novel approach enhances neuromuscular function in patients with Duchenne muscular dystrophy
New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular dystrophy (DMD). In preclinical DMD mouse models, investigators demonstrated ...
Findings published in The American Journal of Pathology identify GLUD1 enzyme as a potential therapeutic target for muscle restoration through metabolic reprogramming, addressing clinically unmet need ...
Researchers at Johns Hopkins Medicine report that an experimental drug first developed to treat kidney disease prolongs survival and improves muscle function in mice genetically engineered to develop ...
Johns Hopkins Medicine researchers discover that blocking the ion channel called TRPC6 in genetically modified mice with severe or moderate Duchenne muscular dystrophy (DMD) substantially improves ...
Skeletal muscle is the type of muscle that controls movement. Problems with these muscles can be minor, life-threatening, or ongoing problems that make it hard to perform basic daily activities.
Human movement is reciprocal in nature: Opposing muscle groups must coordinate for proper movement. Muscle length and strength between opposing muscle groups need to be in balance for normal movement ...
Researchers report that an experimental drug first developed to treat kidney disease prolongs survival and improves muscle function in mice genetically engineered to develop a severe form of Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results